FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 624 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Extension of Indications for Tegafur December 24, 2021 Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... January 5, 2023 A College Senior vs. A Global Pandemic September 30, 2020 Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance December 4, 2025 Load more HOT NEWS Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in... Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer How Becky is helping her children to keep their dad’s memory... EMA Recommends Extension of Therapeutic Indications for Cabozantinib
